Cargando…
The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
Treatment for Hodgkin lymphoma (HL) has evolved considerably from the time it was originally described in the 19th century with many patients now being cured with frontline therapy. Despite these advances, upwards of 10% of patients experience progressive disease after initial therapy with an even h...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877886/ https://www.ncbi.nlm.nih.gov/pubmed/35207685 http://dx.doi.org/10.3390/jpm12020197 |